-14%

New

ARA-290 10 mg

Original price was: 34,99 €.Current price is: 29,99 €. with VAT

ARA-290 (cibinetide) is a cyclic 11-amino acid peptide derived from erythropoietin. It activates the tissue-protective IRR (Innate Repair Receptor) without stimulating red blood cell production —it is precisely this selectivity that makes it a subject of research in neuroprotection, neuropathic pain, and tissue repair.

Purity ≥ 98% – Each batch verified by HPLC; COA available upon request
10 mg of lyophilized powder, store at −20 °C
Shipped within 48 hours

In stock

Dosage calculator

Quantity discount

Quantity	Price	% Discount
7+	26,99 €	10%
4+	28,49 €	5%

Category: Research on Tissue Regeneration and Healing

All products are sold exclusively for the purpose of scientific research and development.
The chemical substances may not be used as a medicine, drug, active substance, medical device, cosmetic product, substance for the manufacture of a cosmetic product, or as a substance for human consumption, i.e. as a food or nutritional supplement, or in any other similar way on humans or animals.

All customers MUST be at least 18 years of age to purchase our products.

Laboratory-tested

Fast and Discreet Shipping

Purity Guarantee

98%+

Description

ARA-290 10 mg – Erythropoietin Derivative for Research into Neuroprotection and Regeneration

⚠️ Legal Notice: ARA-290 is intended exclusively for scientific and research purposes. It is not intended for human use as a medication, dietary supplement, or cosmetic product. Sale exclusively to individuals over the age of 18.

What is ARA-290 (cibinetide)?

ARA-290, also known as cibinetide, is a cyclic peptide composed of 11 amino acids derived from a structural region of erythropoietin (EPO). It was developed and patented by Araim Pharmaceuticals (USA) with the aim of isolating the tissue-protective properties of EPO from its undesirable hematopoietic effects.
Erythropoietin is an endogenous glycoprotein hormone primarily responsible for regulating red blood cell production (erythropoiesis). However, research has revealed that EPO also acts through another receptor system— the INNATE REPAIR RECEPTOR (IRR) —thereby mediating tissue-protective and anti-inflammatory effects independent of erythropoiesis.
ARA-290 was designed to selectively activate IRR without binding to the classical erythropoietin receptor (EPOR), thereby avoiding thrombotic and other risks associated with its hematopoietic effect. This selectivity makes ARA-290 an attractive subject for research in longer-term non-hematological studies.
Important: ARA-290 is not approved as a drug in the European Union or the United States. The available data are derived from preclinical studies and Phase 1–2 clinical trials.

Key feature: tissue protection without erythropoietin activity

The most significant research aspect of ARA-290 is its ability to activate EPO’s tissue-protective signaling pathways without stimulating erythropoiesis. This distinction is crucial for several reasons:

Long-term administration of erythropoietin increases hematocrit (the percentage of red blood cells in the blood), which increases blood viscosity and the risk of thromboembolic complications.
ARA-290 does not present these risks —no stimulation of erythropoiesis or changes in hematocrit were observed in preclinical and Phase 1–2 clinical studies.
This feature makes it possible to study longer-term research protocols without hematological concerns, which is valuable from a scientific standpoint.

Research has identified IRR (Innate Repair Receptor) as a heterodimer consisting of EPOR and the beta-common chain (βc, also known as CD131). This receptor is expressed primarily in non-neural and neural tissues (not in erythroid progenitors), which explains the tissue selectivity of ARA-290.

Mechanism of Action – INNATE REPAIR RECEPTOR (IRR)

Activation of a tissue-protective cytokine receptor

ARA-290 binds to and activates the INNATE REPAIR RECEPTOR (IRR), also known as TPCR (Tissue Protective Cytokine Receptor). This receptor is a heterodimer composed of: – Erythropoietin receptor (EPOR) – one subunit – Beta-common chain (βc, CD131) – the second subunit, shared with receptors for IL-3, IL-5, and GM-CSF
Activation of IRR triggers intracellular signaling cascades involving the PI3K/Akt and JAK2/STAT5 pathways, which are associated with anti-apoptotic and anti-inflammatory effects in various tissues.

Department of Tissue-Protective and Hematopoietic Effects of EPO

Conventional erythropoietin acts through homodimeric EPOR (two EPOR subunits), leading to hematopoietic activation. ARA-290 was structurally designed to interact preferentially with IRR (the EPOR–βc heterodimer), rather than with homodimeric EPOR. This selective targeting is the basis for its distinct pharmacological profile.
Sources: Brines M. et al., PNAS (2008); van der Linden D. et al., PLoS ONE (2015); Niesters M. et al., Anesthesiology (2014)

ARA-290 Research Areas

Neuroprotection and dorsal root ganglia (DRG)

One of the key areas of research for ARA-290 is neuroprotection at the level of the dorsal root ganglia (DRG) —clusters of nerve cells (sensory neurons) located along the spinal cord. The DRGs are responsible for transmitting sensory signals, including pain. Preclinical studies have demonstrated the protective effect of ARA-290 on these neurons in models of peripheral neuropathy.

Research on Neuropathic Pain

Based on preclinical research, Araim Pharmaceuticals has initiated Phase 2 clinical trials focused on neuropathic pain associated with small fiber neuropathy (SFN) —a form of peripheral neuropathy affecting small unmyelinated nerve fibers. Results from pilot clinical trials showed a reduction in neuropathic pain symptoms and an improvement in nerve fiber density (skin biopsy IENF density) compared to placebo.
These results are preliminary and come from small studies. Their clinical relevance requires confirmation in larger randomized controlled trials.

Inflammatory Processes and Tissue Repair

ARA-290 is also being studied in the areas of inflammatory processes and tissue repair. Preclinical models demonstrate its anti-inflammatory effects through modulation of the cytokine response and a reduction in inflammatory cell infiltration. In a model of diabetic nephropathy, a protective effect on renal tissue was observed.

Clinical Research Context

Araim Pharmaceuticals has conducted several Phase 1 and 2 clinical trials with ARA-290 (cibinetide):

Phase 1: Demonstration of safety and tolerability in healthy volunteers. Confirmation of the absence of hematopoietic activity.
Phase 2 – Small Fiber Neuropathy (SFN): A pilot study documented a statistically significant reduction in neuropathic pain symptoms and an improvement in intraepidermal nerve fiber density (IENFD).
Phase 2 – Sarcoidosis with Neuropathy: The ARA-290 Study in Patients with Sarcoidosis Complicated by Small-Fiber Neuropathy.

Important Notice: ARA-290 is not approved as a drug in the EU or the U.S. Clinical studies have not demonstrated sufficient efficacy to support regulatory approval for any indication. The product sold on jacked.sk is a research compound, not a drug.

Comparison of ARA-290 vs. Erythropoietin (EPO)

Property	Erythropoietin (EPO)	ARA-290 (cibinetide)
Receptor	Homodimeric EPOR (hematopoietic)	IRR / TPCR (EPOR–βc heterodimer)
Erythropoietic activity	YES – stimulation of erythrocyte production	NO – no hematopoietic activity
Tissue-protective activity	Partial (via IRR)	Primary function
Risk of Thrombosis	Increased with long-term use	Not reported in Phase 1–2 studies
Clinical Use	Anemia associated with CKD, chemotherapy, and HIV	In the research stage (Phase 2)
Usage on jacked.sk	N/A (not in the catalog)	For scientific research purposes only

Technical Specifications

Parameter	Value
Chemical name	ARA-290 (cibinetide)
Origin	A cyclic peptide derived from erythropoietin (EPO)
Sequence length	11 amino acids (cyclic structure)
Molecular weight	~1,200 Da
CAS Number	1208243-50-8
Form	Lyophilized (freeze-dried) white powder
Contents per package	10 mg
Purity	≥ 98% (HPLC-verified)
Recommended storage conditions	−20 °C, protected from light and moisture
Intended Use	For scientific research purposes only

Frequently Asked Questions About ARA-290

What is ARA-290, and how is it related to erythropoietin?

ARA-290 (cibinetide) is an 11-amino acid cyclic peptide derived from a structural domain of erythropoietin (EPO). It was designed to activate the tissue-protective IRR receptor without stimulating erythropoiesis (the production of red blood cells).

Why is the absence of erythropoietin activity of interest to researchers?

Conventional EPO, when administered over the long term, increases hematocrit levels and the risk of thrombosis. ARA-290 does not exhibit these adverse effects (as confirmed in Phase 1–2 studies), which opens up possibilities for longer-term research into tissue protection without hematological concerns.

In what clinical trials has ARA-290 been tested?

Araim Pharmaceuticals has conducted Phase 2 trials for small fiber neuropathy (SFN) and sarcoidosis with neuropathy. Preliminary results were positive; however, ARA-290 has not been approved as a drug. Details are available on ClinicalTrials.gov.

How pure is ARA-290 on jacked.sk?

ARA-290 from jacked.sk has a purity of ≥98%, verified by HPLC. A Certificate of Analysis (COA) is available upon request.

How should ARA-290 be stored?

Store unopened packages at −20 °C, protected from light and moisture. Avoid repeated thawing and freezing.

Is ARA-290 approved as a drug?

No. ARA-290 (cibinetide) is not approved as a drug in the EU or the U.S. It is sold exclusively as a research compound for scientific purposes to individuals over the age of 18.

⚠️ Warning – Intended exclusively for research purposes

All products sold on jacked.sk are intended EXCLUSIVELY for scientific research purposes. They are not intended for use as a medicine, drug, dietary supplement, or cosmetic product, nor for human or veterinary use. The results cited in the descriptions are based on preclinical studies (in vitro, animal models) and cannot be automatically extrapolated to human use. Sale restricted to individuals over the age of 18. By purchasing this product, the customer confirms that they are a professional researcher and will use the product solely in accordance with applicable laws.